

The future of nanoparticles as a potential substitute for antibiotics

Rupak Roy

SHRM Biotechnologies Pvt. Ltd., Kolkata, West Bengal, India

ARTICLE HISTORY

Received 4 August 2023; Revised 28 August 2023; Accepted 4 September 2023

Antibiotic Resistance Challenge

Antibiotic resistance has become an urgent global health concern. The misuse of antibiotics in healthcare, agriculture, and veterinary practices has accelerated the development of resistant strains of bacteria. This escalating problem has rendered many antibiotics ineffective, leaving patients vulnerable to once-treatable infections. The World Health Organization (WHO) has warned that we are moving toward a "post-antibiotic era" where common infections and minor injuries could once again become life-threatening [1]. The development of new antibiotics has stagnated, as the costs and challenges associated with their discovery and approval have deterred pharmaceutical companies from investing in research and development. It is evident that we need innovative strategies to combat this crisis, and nanoparticles have emerged as a compelling candidate.

Nanoparticles: A Glimpse into the Future

Nanoparticles are materials with at least one dimension at the nanoscale, typically ranging from 1 to 100 nanometers [2]. They possess unique physical and chemical properties that distinguish them from their bulk counterparts. In recent years, researchers have increasingly explored the potential of nanoparticles as therapeutic agents, particularly in the field of microbiology [3-5].

Nanoparticles Offer Several Advantages Over Traditional Antibiotics

Broad-Spectrum Activity: Some nanoparticles, such as silver and copper nanoparticles, exhibit broad-spectrum antimicrobial properties, effectively targeting a wide range of bacteria, fungi, and even viruses [6,7].

Reduced Resistance: The mechanisms of nanoparticle action differ from those of antibiotics, making it harder for bacteria to develop resistance. This could potentially extend the effective lifespan of antimicrobial agents [8].

Targeted Delivery: Nanoparticles can be engineered to selectively target pathogens while sparing beneficial microbes, minimizing collateral damage to the host microbiome [9].

Synergistic Effects: Nanoparticles can work synergistically with existing antibiotics, enhancing their efficacy and potentially reducing the required dosage [10].

Biofilm Disruption: Biofilms, protective communities of bacteria, are notoriously resistant to antibiotics. Nanoparticles have shown promise in disrupting biofilms, opening new avenues for treating chronic and persistent infections [11].

Versatile Applications: Beyond direct antimicrobial activity, nanoparticles can be utilized for drug delivery, imaging, and diagnostics, expanding their utility in the field of microbiology [12-14].

Challenges and Future Directions

While the potential of nanoparticles in combating infections is undeniable, several challenges and questions remain:

Safety: The safety of nanoparticles for human use must be thoroughly investigated. Concerns about their potential toxicity and long-term effects on the environment necessitate rigorous research.

Regulation: The regulatory framework for nanoparticle-based antimicrobials is in its infancy. Developing clear guidelines and standards is crucial to ensure their safe and effective use.

Mechanisms of Action: Understanding the precise mechanisms of nanoparticle action on microbes is essential for optimizing their design and application.

Resistance: While nanoparticle resistance is less likely, it is not impossible. Ongoing surveillance is needed to monitor the emergence of resistance mechanisms.

Cost-Effectiveness: Assessing the cost-effectiveness of nanoparticle-based therapies compared to traditional antibiotics will be critical for their adoption in healthcare systems worldwide.

Interdisciplinary Collaboration: Progress in this field requires collaboration between microbiologists, materials scientists, pharmacologists, and clinicians. Encouraging cross-disciplinary research is essential.

Conclusions

As we stand on the precipice of a post-antibiotic era, the potential of nanoparticles as a substitute for antibiotics represents a ray of hope. Research and development of nanoparticle-based antimicrobials offers a promising path forward in our battle against infectious diseases. However, this journey is not without challenges and uncertainties. It requires dedication, collaboration, and a commitment to rigorous scientific inquiry. In the pages of the Journal of Microbiology and Infection, we will explore the latest developments, breakthroughs, and challenges in this exciting field. Our goal is to provide a platform for scientists, researchers, and clinicians to share their knowledge, insights, and innovations, driving progress in the quest for effective alternatives to antibiotics.

*Correspondence: Dr. Rupak Roy, SHRM Biotechnologies Pvt. Ltd., Kolkata, West Bengal, India, e-mail: rupak@shrm.bio.com

Our journal presents cutting-edge research, and we invite you to participate in the dialogue that will shape the future of microbiology and infection control with us. Together, we can work towards a safer, healthier world, where infectious diseases are no longer the formidable adversaries they are today.

Disclosure statement

No potential conflict of interest was reported by the author.

References

1. World Health Organization. Antimicrobial resistance: global report on surveillance, <https://onehealthtrust.org/projects/who-collaborating-center-who-cc-for-antimicrobial-resistance/?gclid=CjwKCAjw7c2pBhAZEiwA> (Accessed on July 2019).
2. Khan I, Saeed K, Khan I. Nanoparticles: Properties, applications and toxicities. *Arab J Chem*. 2019;12(7):908-931.
3. Yetisgin AA, Cetinel S, Zuvun M, Kosar A, Kutlu O. Therapeutic nanoparticles and their targeted delivery applications. *Molecules*. 2020;25(9):2193.
4. Mba IE, Nweze EI. Nanoparticles as therapeutic options for treating multidrug-resistant bacteria: Research progress, challenges, and prospects. *World J Microbiol Biotechnol*. 2021;37:1-30.
5. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. *Front Mol Biosci*. 2020;7:193.
6. Bruna T, Maldonado-Bravo F, Jara P, Caro N. Silver nanoparticles and their antibacterial applications. *Int J Mol Sci*. 2021;22(13):7202.
7. Sharmin S, Rahaman MM, Sarkar C, Atolani O, Islam MT, Adeyemi OS. Nanoparticles as antimicrobial and antiviral agents: A literature-based perspective study. *Heliyon*. 2021;7(3).
8. Sánchez-López E, Gomes D, Esteruelas G, Bonilla L, Lopez-Machado AL, Galindo R, et al. Metal-based nanoparticles as antimicrobial agents: an overview. *Nanomaterials*. 2020;10(2):292.
9. Song W, Anselmo AC, Huang L. Nanotechnology intervention of the microbiome for cancer therapy. *Nat Nanotechnol*. 2019;14(12):1093-1103.
10. Ipe DS, Kumar PS, Love RM, Hamlet SM. Silver nanoparticles at biocompatible dosage synergistically increases bacterial susceptibility to antibiotics. *Front Microbiol*. 2020;11:1074.
11. Alabresm A, Chandler SL, Benicewicz BC, Decho AW. Nanotargeting of resistant infections with a special emphasis on the biofilm landscape. *Bioconjug Chem*. 2021;32(8):1411-1430.
12. Afzal O, Altamimi AS, Nadeem MS, Alzarea SI, Almalki WH, Tariq A, et al. Nanoparticles in Drug Delivery: From History to Therapeutic Applications. *Nanomaterials*. 2022;12(24):4494.
13. Han X, Xu K, Taratula O, Farsad K. Applications of nanoparticles in biomedical imaging. *Nanoscale*. 2019;11(3):799-819.
14. Thwala LN, Ndlovu SC, Mpofu KT, Lugongolo MY, Mthunzi-Kufa P. Nanotechnology-Based Diagnostics for Diseases Prevalent in Developing Countries: Current Advances in Point-of-Care Tests. *Nanomaterials*. 2023;13(7):1247.